# Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

> **NCT00667394** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 42 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma
- Anaplastic Astrocytoma
- Anaplastic Oligodendroglioma
- Anaplastic Mixed Oligoastrocytoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** MLN-518 (Tandutinib)
- **PROCEDURE:** Quality-of-life assessment

## Key facts

- **NCT ID:** NCT00667394
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2015-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00667394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00667394, "Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00667394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*